Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Consolidation Therapy in Locally Advanced NSCLC
NCT05758116Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2022
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-Free Survival at 6 months. Started Jul 2022; status: completed.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05758116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05758116.